Publications en collaboration avec des chercheurs de Pitié-Salpêtrière Hospital (42)

2016

  1. Infection-related and -unrelated malignancies, HIV and the aging population

    HIV Medicine, Vol. 17, Núm. 8, pp. 590-600

2015

  1. Changing utilization of Stavudine (d4T) in HIV-positive people in 2006-2013 in the EuroSIDA study

    HIV Medicine, Vol. 16, Núm. 9, pp. 533-543

  2. Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

    PLoS Medicine, Vol. 12, Núm. 3

  3. Geographic and Temporal Trends in the Molecular Epidemiology and Genetic Mechanisms of Transmitted HIV-1 Drug Resistance: An Individual-Patient- and Sequence-Level Meta-Analysis

    PLoS Medicine, Vol. 12, Núm. 4

2014

  1. A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe

    Infection, Vol. 42, Núm. 4, pp. 757-762

  2. Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: The D:A:D study

    BMC Nephrology, Vol. 15, Núm. 1

  3. High rate of hepatitis C virus (HCV) recurrence in HIV-infected individuals with spontaneous HCV RNA clearance

    HIV Medicine, Vol. 15, Núm. 10, pp. 615-620

  4. Immuno-virological discordance and the risk of non-AIDS and AIDS events in a large observational cohort of HIV-patients in Europe

    PLoS ONE, Vol. 9, Núm. 1

  5. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

2013

  1. Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients

    PLoS ONE, Vol. 8, Núm. 5

  2. Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-Week results of the VIKING study

    Journal of Infectious Diseases, Vol. 207, Núm. 5, pp. 740-748

2012

  1. Hepatitis c virus viremia increases the Incidence of chronic kidney disease in HIV-infected Patients

    AIDS, Vol. 26, Núm. 15, pp. 1917-1926

  2. Regional differences in AIDS and non-AIDS related mortality in HIV-positive individuals across Europe and Argentina: The EuroSIDA study

    PLoS ONE, Vol. 7, Núm. 7

2011

  1. A376s in the connection subdomain of HIV-1 reverse transcriptase confers increased risk of virological failure to nevirapine therapy

    Journal of Infectious Diseases, Vol. 204, Núm. 5, pp. 741-752

2010

  1. Dialysis and renal transplantation in HIV-infected patients: A European survey

    Journal of Acquired Immune Deficiency Syndromes, Vol. 55, Núm. 5, pp. 582-589

2009

  1. Variable Impact on Mortality of AIDS-Defining Events Diagnosed during Combination Antiretroviral Therapy: Not All AIDS-Defining Conditions Are Created Equal

    Clinical Infectious Diseases, Vol. 48, Núm. 8, pp. 1138-1151

  2. When and how to use maraviroc in HIV-infected patients

    AIDS, Vol. 23, Núm. 18, pp. 2377-2385

2008

  1. Antiretroviral drugs and liver injury

    AIDS, Vol. 22, Núm. 1, pp. 1-13

  2. Care of HIV patients with chronic hepatitis B: Updated recommendations from the HIV-Hepatitis B Virus International Panel

    AIDS, Vol. 22, Núm. 12, pp. 1399-1410

  3. Comparison of genotypic resistance profiles and virological response between patients starting nevirapine and efavirenz in EuroSIDA

    AIDS, Vol. 22, Núm. 3, pp. 367-376